Review Article
Open Access

# Clinical microbiology of fungal infections: from diagnosis to drug resistance

## Abstract

Fungal infections represent a growing global health challenge, particularly among immunocompromised individuals, critically ill patients, and those undergoing prolonged antibiotic or immunosuppressive therapy. The clinical microbiology of fungal infections plays a central role in bridging the gap between early diagnosis and effective treatment outcomes. Accurate diagnosis begins with conventional methods such as direct microscopy using potassium hydroxide (KOH) preparations, Gram staining, and culture on selective media like Sabouraud dextrose agar, which remain foundational for identifying common fungal pathogens. However, these approaches are often slow, leading to delays in initiating appropriate therapy. Advances in diagnostic microbiology, including antigen detection assays such as galactomannan and β-D-glucan tests, have significantly improved early detection of invasive fungal infections. Molecular techniques like polymerase chain reaction (PCR), DNA sequencing, and MALDI-TOF mass spectrometry now enable rapid and precise species-level identification, which is critical given the varying antifungal susceptibility profiles among species of Candida, Aspergillus, and Cryptococcus. Despite these improvements, antifungal drug resistance has emerged as a major clinical concern. Mechanisms of resistance include mutations in target enzymes such as ERG11 in azole-resistant Candida species, overexpression of efflux pumps, biofilm-associated tolerance, and alterations in cell wall composition that reduce drug binding. The widespread and sometimes empirical use of antifungal agents has further accelerated resistance development. Clinical microbiology laboratories play a vital role in antifungal susceptibility testing and in guiding evidence-based therapy tailored to local epidemiological trends. Integration of rapid diagnostics with resistance profiling is essential for improving patient outcomes. Ultimately, a comprehensive understanding of fungal pathogenesis, diagnostic innovations, and resistance mechanisms is crucial for managing fungal diseases effectively in modern clinical settings.

**Keywords:** Microbial infections, fungal infection, MDR

Volume 14 Issue 2 - 2026

Vasudevan Ranganathan,[1] Padma Madham[2]
[1]Department of Biotechnology, Aurora's Degree & PG College, India
[2]Department of Microbiology, Aurora's Degree & PG College, India

**Correspondence:** Vasudevan Ranganathan, Department of Biotechnology, Aurora's Degree & PG College, India

**Received:** June 13, 2026 | **Published:** June 22, 2026

## Introduction

Fungal infections have emerged as a significant and growing concern in modern clinical practice, driven by an increasing population of immunocompromised patients, widespread use of invasive medical procedures, and the expanding burden of chronic diseases such as diabetes, cancer, and HIV/AIDS. Opportunistic fungal pathogens, once considered relatively uncommon causes of morbidity, are now recognized as major contributors to hospital-acquired and community-acquired infections worldwide. Species belonging to genera such as *Candida*, *Aspergillus*, *Cryptococcus*, and emerging non-*albicans Candida* species are frequently implicated in invasive infections that can affect the bloodstream, respiratory tract, central nervous system, and other vital organs.[1] The clinical impact of these infections is compounded by their often-nonspecific clinical presentation, which makes early diagnosis challenging and contributes to high mortality rates, particularly in critically ill patients. As a result, clinical microbiology has become central to the timely detection, identification, and management of fungal diseases. The diagnosis of fungal infections has traditionally relied on direct microscopic examination, culture-based methods, and histopathological evaluation. While these techniques remain fundamental, they are often time-consuming and may lack sensitivity, particularly in cases of deep-seated or disseminated infections where organism burden is low.[2] Culture methods, although considered the gold standard for species identification, may require several days to weeks for definitive results, delaying the initiation of appropriate antifungal therapy. Furthermore, some fungal pathogens are fastidious or non-culturable under routine laboratory conditions, leading to diagnostic limitations. These challenges have driven the development and adoption of advanced diagnostic modalities in clinical microbiology laboratories.[3]

In recent years, non-culture-based diagnostic techniques have significantly transformed the landscape of fungal detection. Antigen-based assays, such as galactomannan detection for *Aspergillus* and cryptococcal antigen testing for *Cryptococcus neoformans*, have enabled earlier diagnosis of invasive infections. Similarly, the measurement of serum (1→3)-β-D-glucan has provided a broad-spectrum marker for invasive fungal disease, although with some limitations in specificity. Molecular diagnostic tools, including polymerase chain reaction (PCR), nucleic acid amplification tests, and next-generation sequencing, have further enhanced the speed and accuracy of fungal identification. In addition, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has revolutionized routine laboratory workflows by enabling rapid species-level identification with high precision.[4] These advancements have collectively improved diagnostic turnaround times and facilitated earlier initiation of targeted antifungal therapy, which is critical for improving patient outcomes. Despite significant progress in diagnostic methodologies, the management of fungal infections continues to be complicated by the rising incidence of antifungal resistance. Resistance has been increasingly reported across major pathogenic fungi, particularly among *Candida auris*, azole-resistant *Aspergillus fumigatus*, and non-*albicans Candida* species

such as *Candida glabrata*. The mechanisms underlying antifungal resistance are multifactorial and include genetic mutations in drug target enzymes, upregulation of efflux pumps, biofilm formation on medical devices, and alterations in membrane sterol composition.[5] The widespread use of antifungal agents, both prophylactically and therapeutically, has further contributed to the selection pressure driving resistant strains. This trend poses a serious global health threat, as it limits therapeutic options and is associated with increased morbidity, mortality, and healthcare costs.

Clinical microbiology laboratories play a pivotal role in addressing these challenges by integrating diagnostic accuracy with antifungal susceptibility testing. Standardized methods such as broth microdilution and automated susceptibility systems help determine minimum inhibitory concentrations (MICs), guiding clinicians in selecting appropriate antifungal therapy. Surveillance of local and regional resistance patterns is equally important for informing empirical treatment strategies. Moreover, the integration of molecular resistance markers and rapid diagnostic platforms holds promise for the future of personalized antifungal therapy.[6] The combination of timely diagnosis, precise species identification, and resistance profiling is essential for optimizing clinical outcomes. The field of clinical microbiology is central to the effective management of fungal infections, spanning the continuum from early detection to the identification of drug resistance. As fungal pathogens continue to evolve and resistance becomes increasingly prevalent, there is a critical need for continued advancements in diagnostic technologies, antifungal drug development, and surveillance systems. A comprehensive understanding of fungal pathogenesis, coupled with state-of-the-art laboratory techniques, is essential to combat the rising global burden of fungal diseases and improve patient care outcomes in both hospital and community settings.[7]

## Fungal pathogenesis

Fungal pathogenesis is a complex and multifactorial process that involves the dynamic interaction between the fungal organism and the host immune system. Unlike many bacterial pathogens, fungi are eukaryotic organisms that share several cellular and molecular similarities with human host cells, making selective targeting and immune recognition more challenging. The ability of fungi to cause disease depends on a combination of intrinsic virulence factors, environmental adaptability, and host susceptibility.[8] While most fungi exist as harmless commensals or environmental saprophytes, certain species can transition into opportunistic pathogens under favorable conditions such as immunosuppression, disruption of normal microbiota, or breaches in physical barriers. Common pathogenic fungi include species of *Candida*, *Aspergillus*, *Cryptococcus*, and dimorphic fungi such as *Histoplasma capsulatum* and *Blastomyces dermatitidis*, all of which exhibit unique mechanisms of host invasion and survival. One of the critical steps in fungal pathogenesis is adherence to host tissues and medical devices, which is mediated by specific adhesins and surface proteins.[9]

In *Candida albicans*, for instance, cell surface glycoproteins facilitate attachment to epithelial cells and prosthetic materials, leading to colonization and biofilm formation. Biofilms are structured microbial communities embedded in an extracellular matrix that provides protection against host immune responses and antifungal agents, significantly contributing to persistent and recurrent infections. Following adhesion, many fungi demonstrate morphological plasticity, particularly the ability to switch between yeast and hyphal forms. This dimorphic transition is a major virulence determinant in *Candida albicans*, enabling tissue invasion, immune evasion, and dissemination.[10] Hyphal forms are particularly associated with tissue penetration and damage, while yeast forms are more suited for dissemination through the bloodstream. Immune evasion is another key component of fungal pathogenesis. Fungi have evolved several strategies to avoid detection and destruction by the host immune system. These include masking of pathogen-associated molecular patterns (PAMPs) such as β-glucans, secretion of enzymes that degrade host immune molecules, and resistance to phagocytosis by macrophages and neutrophils.[11]

Some fungi, such as *Cryptococcus neoformans*, possess a polysaccharide capsule that inhibits phagocytosis and suppresses inflammatory responses. Additionally, fungi can survive within host immune cells by resisting oxidative killing mechanisms, thereby using macrophages as a niche for dissemination throughout the body. The ability to withstand oxidative stress, nutrient limitation, and temperature changes further enhances fungal survival within the host environment. Tissue damage during fungal infections results from both direct fungal activity and host-mediated immune responses.[12] Fungi secrete a variety of hydrolytic enzymes, including proteases, lipases, and phospholipases, which degrade host tissues and facilitate invasion. Iron acquisition systems also play a crucial role in pathogenesis, as iron is essential for fungal growth but is tightly sequestered within the host. Fungi produce siderophores and other iron-scavenging molecules to overcome this limitation. In addition, the host inflammatory response, while essential for controlling infection, can contribute significantly to tissue injury, particularly in invasive pulmonary aspergillosis where excessive neutrophil activation leads to lung damage.[13] Host factors play an equally important role in determining susceptibility to fungal disease. Immunocompromised states such as neutropenia, HIV infection, organ transplantation, prolonged corticosteroid therapy, and uncontrolled diabetes mellitus greatly increase the risk of invasive fungal infections. The integrity of the host microbiome also serves as a protective barrier, and disruption due to broad-spectrum antibiotic use can promote fungal overgrowth, particularly in *Candida* species. Genetic predisposition, including defects in pattern recognition receptors and cytokine signaling pathways, has also been associated with increased vulnerability to fungal infections.[14] Fungal pathogenesis is the result of a delicate balance between fungal virulence mechanisms and host defense systems. Successful pathogens are those that can adapt to changing host environments, evade immune detection, acquire essential nutrients, and resist antimicrobial therapy. Understanding these mechanisms is crucial for the development of improved diagnostic strategies, targeted antifungal therapies, and preventive measures aimed at reducing the global burden of fungal diseases.[15]

## Diagnostic strategies

Diagnostic strategies for fungal infections are essential for the timely detection, accurate identification, and effective management of both superficial and invasive mycoses. The diagnosis of fungal diseases is often challenging due to their nonspecific clinical presentation, slow growth rates, and overlap with bacterial or viral infections. Therefore, a combination of traditional microbiological techniques and modern molecular and immunological approaches is commonly employed in clinical settings. Early and accurate diagnosis is particularly critical in immunocompromised patients, where delayed treatment can significantly increase morbidity and mortality.[16] Diagnostic approaches are broadly categorized into conventional methods, non-culture-based assays, and advanced molecular and proteomic techniques, each contributing uniquely to the diagnostic workflow. Conventional diagnostic methods remain the foundation

**Citation:** Ranganathan V, Madham P. Clinical microbiology of fungal infections: from diagnosis to drug resistance. *J Bacteriol Mycol Open Access*. 2026;14(2):74–80. DOI: 10.15406/jbmoa.2026.14.00433

of fungal detection in clinical microbiology laboratories. Direct microscopic examination of clinical specimens using potassium hydroxide (KOH) mounts, calcofluor white staining, and Gram staining provides rapid preliminary evidence of fungal presence. Histopathological examination of tissue samples using special stains such as Periodic Acid–Schiff (PAS) and Gomori methenamine silver (GMS) is particularly useful for identifying invasive fungal elements within host tissues and assessing tissue invasion.[17]

Culture-based methods, using media such as Sabouraud dextrose agar, remain the gold standard for definitive identification of fungal pathogens. However, fungal cultures often require prolonged incubation periods ranging from several days to weeks, and some species may exhibit slow or poor growth, limiting their diagnostic utility in urgent clinical scenarios. To overcome the limitations of culture-based diagnostics, non-culture-based assays have gained significant importance in recent years. Antigen detection tests, such as galactomannan assay for *Aspergillus* infections and cryptococcal antigen testing for *Cryptococcus neoformans*, enable early and non-invasive diagnosis of invasive fungal infections. The (1→3)-β-D-glucan assay is another widely used biomarker that detects a broad range of fungal pathogens by identifying a key component of fungal cell walls.[18] Although highly sensitive, these assays may lack specificity and can yield false-positive results due to cross-reactivity or contamination. Serological tests detecting antibodies against fungal pathogens are useful in certain endemic mycoses but are often limited in immunocompromised patients who may not mount adequate immune responses. Molecular diagnostic techniques have revolutionized fungal identification by offering rapid, sensitive, and species-level detection. Polymerase chain reaction (PCR)-based assays allow direct detection of fungal DNA from clinical samples, significantly reducing turnaround time compared to traditional culture methods. Real-time PCR further enhances sensitivity and enables quantification of fungal load, which can be useful in monitoring treatment response.[19] DNA sequencing of conserved genetic regions such as ITS (internal transcribed spacer) regions provide precise species identification, particularly for cryptic or closely related fungal species. Next-generation sequencing (NGS) has further expanded diagnostic capabilities by enabling unbiased detection of a wide range of fungal pathogens, including rare and emerging species, directly from clinical specimens.

Proteomic approaches, particularly matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), have become increasingly integrated into routine diagnostic workflows. MALDI-TOF MS allows rapid identification of fungal isolates based on protein spectral patterns, offering high accuracy and significantly reduced turnaround times compared to conventional biochemical methods.[20] This technology is especially valuable in identifying *Candida* and *Aspergillus* species at the species complex level, which is critical for guiding antifungal therapy due to varying susceptibility profiles among species. In addition to laboratory-based diagnostics, imaging techniques play a supportive role in the diagnosis of invasive fungal infections. Radiological investigations such as computed tomography (CT) and magnetic resonance imaging (MRI) are particularly useful in detecting pulmonary, sinus, and central nervous system involvement. Specific radiological signs, such as the "halo sign" and "air crescent sign" in invasive pulmonary aspergillosis, provide important diagnostic clues when interpreted in conjunction with clinical and laboratory findings.[21] However, imaging findings are often nonspecific and must be corroborated with microbiological evidence for definitive diagnosis. Antifungal susceptibility testing is another critical component of diagnostic strategies, particularly in the context of rising antifungal resistance. Standardized methods such as broth microdilution and automated systems help determine minimum inhibitory concentrations (MICs), guiding clinicians in selecting appropriate antifungal therapy. Detection of resistance-associated genetic mutations through molecular methods is increasingly being incorporated into diagnostic workflows to provide rapid insights into potential treatment failure. Surveillance of local epidemiological patterns of resistance further supports empirical treatment decisions and helps in infection control practices.[22]

Overall, diagnostic strategies for fungal infections require an integrated, multi-modal approach that combines traditional microscopy and culture, advanced immunological assays, molecular diagnostics, proteomic technologies, and susceptibility testing. The synergy of these methods enhances diagnostic accuracy, reduces turnaround time, and improves patient outcomes. As fungal infections continue to rise globally and resistance patterns evolve, continued innovation in diagnostic technologies and their integration into clinical practice remains essential for effective.[23]

## Antibiotic resistance in fungi

The development of antifungal (often mistakenly referred to as "antibiotic") resistance in fungi is an increasingly serious global health concern, driven by the widespread use of antifungal agents in both clinical and agricultural settings. Unlike bacteria, fungi are eukaryotic organisms, which limits the number of selective drug targets and results in a relatively small arsenal of antifungal classes, including azoles, polyenes, echinocandins, and antimetabolites. This limited therapeutic diversity increases selective pressure on fungal populations, facilitating the emergence and spread of resistant strains. Resistance may be intrinsic, where certain fungal species naturally exhibit reduced susceptibility to specific drugs, or acquired, where genetic and phenotypic changes occur during or after antifungal exposure.[24] Over time, the intensive and sometimes inappropriate use of antifungal drugs—such as prolonged prophylaxis in immunocompromised patients or empirical therapy without susceptibility testing—has accelerated resistance development in clinically important fungi. One of the well-studied mechanisms of antifungal resistance involves genetic mutations in drug target enzymes. For example, resistance to azole antifungals in *Candida* species is frequently associated with mutations in the ERG11 gene, which encodes lanosterol 14-α-demethylase, the key enzyme targeted by azoles. These mutations reduce drug binding affinity, thereby decreasing drug efficacy.[25] Additionally, overexpression of efflux pump genes such as CDR1, CDR2, and MDR1 leads to increased expulsion of antifungal agents from the fungal cell, lowering intracellular drug concentrations and contributing to multidrug resistance. Similar mechanisms have been observed in *Aspergillus fumigatus*, where mutations in the cyp51A gene confer resistance to triazole antifungals, particularly in strains exposed to agricultural azole compounds.

Biofilm formation is another major contributor to antifungal resistance. Many pathogenic fungi, especially *Candida albicans* and *Candida auris*, can form complex, surface-associated biofilms on medical devices such as catheters and prosthetic valves.[26] These biofilms consist of dense fungal cells embedded in an extracellular matrix that acts as a physical and chemical barrier to antifungal penetration. Cells within biofilms often exhibit altered metabolic states, reduced growth rates, and increased stress tolerance, all of which contribute to decreased antifungal susceptibility. As a result, infections involving biofilms are significantly more difficult to eradicate and frequently require device removal in addition to pharmacological

**Citation:** Ranganathan V, Madham P. Clinical microbiology of fungal infections: from diagnosis to drug resistance. *J Bacteriol Mycol Open Access*. 2026;14(2):74–80. DOI: 10.15406/jbmoa.2026.14.00433

therapy. Phenotypic plasticity also plays an important role in resistance development. Fungi can adapt to environmental stressors, including antifungal exposure, by altering cell wall composition, membrane sterol content, and metabolic pathways. Some species exhibit tolerance rather than true genetic resistance, where survival occurs at higher drug concentrations without stable genetic mutations. This adaptive tolerance can serve as a stepping stone toward stable, heritable resistance.[27]

In addition, the ability of fungi to switch between morphological forms, such as yeast and hyphal states in *Candida albicans*, contributes to survival under antifungal pressure and enhances virulence. Environmental and ecological factors significantly influence the emergence of antifungal resistance. The extensive use of azole compounds in agriculture for crop protection has been linked to the development of resistant environmental strains of *Aspergillus fumigatus*. These resistant spores can be inhaled by humans, leading to infections that are already resistant before clinical exposure to antifungal drugs. Hospital environments also play a critical role, particularly in the spread of multidrug-resistant species such as *Candida auris*, which can persist on surfaces and spread between patients in healthcare settings.[28] Poor infection control practices, prolonged hospitalization, and inadequate sterilization further contribute to transmission. Host-related factors also influence the development and selection of resistant fungal populations. Immunocompromised patients often require long-term antifungal prophylaxis, which creates sustained selective pressure favoring resistant strains. Additionally, inadequate dosing, poor patient adherence, and drug interactions can lead to subtherapeutic antifungal levels, further promoting resistance emergence. The interaction between host immunity and fungal adaptation is dynamic, as fungi exposed to immune stressors such as oxidative bursts and nutrient limitation may undergo genetic and epigenetic changes that enhance survival and drug tolerance.[29] The development of antifungal resistance is a multifactorial process involving genetic mutations, efflux pump overexpression, biofilm formation, phenotypic adaptation, environmental exposure, and clinical misuse of antifungal agents. The convergence of these factors has led to the emergence of highly resistant fungal pathogens that pose significant challenges to clinical management. Addressing this issue requires a combination of improved antifungal stewardship, rapid diagnostic techniques, surveillance of resistance patterns, and the development of novel antifungal agents with new mechanisms of action.[30]

## Management of fungal contagion in modern clinical settings

Management of fungal infections in modern clinical settings requires a comprehensive, multidisciplinary approach that integrates early diagnosis, prompt initiation of appropriate antifungal therapy, infection control measures, and continuous monitoring of patient response. The increasing incidence of invasive fungal diseases, particularly among immunocompromised individuals such as those undergoing chemotherapy, organ transplantation, or long-term corticosteroid therapy, has made fungal management a critical component of contemporary clinical care.[31] Effective management begins with a high index of clinical suspicion, as fungal infections often present with nonspecific symptoms such as fever, respiratory distress, or systemic inflammatory signs that overlap with bacterial or viral infections. Early recognition is essential because delayed treatment is strongly associated with increased morbidity and mortality, especially in invasive candidiasis, aspergillosis, and cryptococcosis. Once a fungal infection is suspected, rapid diagnostic confirmation using clinical microbiology tools is crucial to guide therapy.[32]

Conventional methods such as microscopy and culture remain important, but modern diagnostic strategies including antigen detection assays, molecular techniques, and imaging studies significantly improve diagnostic speed and accuracy. In many clinical settings, empirical antifungal therapy is initiated in high-risk patients even before definitive laboratory confirmation, particularly in intensive care units and hematology-oncology wards. This approach, while sometimes necessary, underscores the importance of antifungal stewardship to prevent unnecessary drug exposure and resistance development.[33]

The choice of antifungal agent depends on the suspected pathogen, site of infection, severity of illness, and patient-specific factors such as renal and hepatic function, prior antifungal exposure, and potential drug interactions. The primary classes of antifungal agents used in clinical management include azoles, echinocandins, polyenes, and flucytosine, each with distinct mechanisms of action and therapeutic roles. Azoles, such as fluconazole, voriconazole, and posaconazole, are widely used due to their broad spectrum and oral availability, making them suitable for both treatment and prophylaxis. Echinocandins, including caspofungin, micafungin, and anidulafungin, are often considered first-line therapy for invasive candidiasis due to their fungicidal activity and favorable safety profile.[34] Amphotericin B, a polyene antifungal, remains a potent broad-spectrum agent reserved for severe or refractory infections, although its use is limited by significant nephrotoxicity and infusion-related adverse effects. Combination therapy is sometimes employed in severe infections or in cases involving resistant organisms, although evidence for routine use varies depending on the clinical scenario. Antifungal stewardship plays a central role in optimizing therapeutic outcomes and minimizing resistance development.[35] This involves selecting the most appropriate drug, dose, and duration of therapy based on microbiological data and clinical guidelines. De-escalation of therapy based on culture results and susceptibility testing is an important strategy to reduce unnecessary broad-spectrum antifungal use. Therapeutic drug monitoring (TDM) is increasingly utilized for agents such as voriconazole and posaconazole to ensure optimal plasma concentrations, improve efficacy, and reduce toxicity. In addition, careful assessment of drug-drug interactions is essential, particularly in critically ill patients receiving multiple medications.[36]

Infection control and prevention strategies are equally important in the management of fungal contagion within healthcare environments. Hospital-acquired fungal infections, especially those caused by multidrug-resistant organisms such as *Candida auris*, require strict adherence to hygiene protocols, including hand hygiene, environmental disinfection, and isolation of infected patients. Proper sterilization of medical devices and minimization of invasive procedures such as central venous catheterization can significantly reduce the risk of nosocomial fungal infections. Surveillance programs within hospitals help track infection trends and identify outbreaks early, enabling timely intervention.[37] Management also extends beyond pharmacological treatment to include supportive care and correction of underlying risk factors. In immunocompromised patients, efforts to restore immune function, such as reducing immunosuppressive therapy when feasible or managing neutropenia, are critical components of treatment. Control of comorbid conditions such as diabetes mellitus is also essential, as hyperglycemia can promote fungal growth and impair immune responses. Nutritional support, management of organ dysfunction, and intensive care support are often required in severe cases of disseminated fungal infections.[38]

Despite advances in antifungal therapy and diagnostics, treatment failure remains a significant challenge due to emerging

**Citation:** Ranganathan V, Madham P. Clinical microbiology of fungal infections: from diagnosis to drug resistance. *J Bacteriol Mycol Open Access*. 2026;14(2):74–80. DOI: 10.15406/jbmoa.2026.14.00433

resistance, biofilm-associated infections, and delayed diagnosis. Resistant pathogens such as azole-resistant *Aspergillus fumigatus* and multidrug-resistant *Candida auris* have complicated clinical decision-making and limited therapeutic options. In such cases, individualized treatment strategies guided by susceptibility testing, expert consultation, and, when necessary, combination antifungal therapy are employed. Ongoing research into novel antifungal agents, immunotherapies, and vaccine development offers hope for improved future management strategies.[39]

The management of fungal infections in modern clinical settings is complex and requires integration of rapid diagnostics, targeted antifungal therapy, infection control practices, and patient-specific considerations. A coordinated approach involving clinicians, microbiologists, pharmacists, and infection control specialists is essential to improve outcomes and reduce the global burden of fungal diseases.[40]

## Methodology

This review was conducted as a narrative literature review to provide a comprehensive overview of the clinical microbiology of fungal infections, including their epidemiology, pathogenesis, laboratory diagnosis, antifungal susceptibility testing, and emerging resistance mechanisms. The review aimed to synthesize current knowledge and identify recent advances and challenges in the diagnosis and management of fungal diseases.

A systematic search of the scientific literature was performed using major biomedical databases, including PubMed, Scopus, Web of Science, and Google Scholar. Publications from January 2016 to December 2025 were considered to ensure inclusion of recent developments in fungal diagnostics and antifungal resistance.

Search terms were selected based on the review objectives and included combinations of the following keywords:

a. Clinical microbiology
b. Fungal infections
c. Medical mycology
d. Invasive fungal diseases
e. Opportunistic fungal pathogens
f. Fungal diagnostics
g. Molecular diagnosis
h. Antifungal susceptibility testing
i. Antifungal resistance
j. Drug resistance mechanisms
k. Emerging fungal pathogens

## Eligibility criteria

The review included:

a. Peer-reviewed original research articles
b. Systematic reviews and meta-analyses
c. Clinical practice guidelines
d. Epidemiological surveillance reports
e. Studies addressing laboratory diagnosis of fungal infections
f. Publications describing antifungal resistance mechanisms
g. Articles focusing on clinically significant fungal pathogens

**a) Data Collection and Extraction**

Relevant articles were screened based on title and abstract, followed by full-text evaluation. Information extracted from selected studies included:

a. Fungal species and taxonomy
b. Clinical significance and disease manifestations
c. Diagnostic methodologies
d. Culture and microscopy findings
e. Serological and molecular diagnostic approaches
f. Antifungal susceptibility testing methods
g. Mechanisms of antifungal resistance
h. Emerging trends in fungal epidemiology

**b) Data Synthesis**

The selected literature was qualitatively analyzed and grouped into the following major themes:

1. Epidemiology and burden of fungal infections
2. Clinically important fungal pathogens
3. Conventional diagnostic methods
4. Advanced molecular and genomic diagnostic techniques
5. Antifungal agents and susceptibility testing
6. Molecular mechanisms of antifungal resistance
7. Emerging challenges and future directions in clinical mycology

The findings were synthesized to highlight recent advances, limitations of current diagnostic approaches, and the growing threat of antifungal resistance.

**c) Quality Assessment**

Preference was given to high-quality studies published in peer-reviewed journals and recommendations issued by recognized organizations such as the World Health Organization, Centers for Disease Control and Prevention, European Confederation of Medical Mycology, and Clinical and Laboratory Standards Institute. The relevance, methodological rigor, and scientific impact of the selected publications were considered during evidence synthesis.

## Discussion

Fungal infections have emerged as a major global health concern, particularly among immunocompromised individuals, patients undergoing intensive medical interventions, transplant recipients, and those with chronic diseases. The increasing incidence of invasive fungal infections has highlighted the critical role of clinical microbiology in the timely diagnosis and effective management of these diseases. Traditional diagnostic methods, including direct microscopy, histopathological examination, and fungal culture, remain important components of routine laboratory practice due to their accessibility and ability to provide definitive organism identification. However, these methods are often limited by low sensitivity, prolonged turnaround times, and difficulties in detecting

fastidious or non-culturable fungi. As a result, significant advances have been made in the development of rapid and highly sensitive diagnostic technologies. Molecular techniques such as polymerase chain reaction (PCR), real-time PCR, DNA sequencing, and next-generation sequencing have substantially improved the detection and identification of fungal pathogens directly from clinical specimens. Similarly, non-culture-based assays, including antigen detection tests such as galactomannan and β-D-glucan, have enhanced the early diagnosis of invasive fungal infections, allowing for prompt initiation of therapy and improved patient outcomes.

The clinical microbiology of fungal infections has also been transformed by a growing understanding of fungal diversity and pathogenicity. While species of *Candida*, *Aspergillus*, *Cryptococcus*, and members of the order *Mucorales* remain among the most significant causes of invasive disease, emerging pathogens have become increasingly recognized in healthcare settings. The global emergence of multidrug-resistant fungal species has created new diagnostic and therapeutic challenges. Among these, *Candida auris* has attracted considerable attention because of its ability to cause outbreaks in healthcare facilities, persist in hospital environments, and exhibit resistance to multiple classes of antifungal drugs. Such developments underscore the importance of accurate species-level identification and continuous epidemiological surveillance. Advanced technologies such as matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) have greatly improved the speed and accuracy of fungal identification, supporting better infection control practices and targeted treatment decisions. A major challenge in the management of fungal infections is the increasing prevalence of antifungal resistance. Resistance has been documented across all major antifungal classes, including azoles, echinocandins, and polyenes.

Multiple mechanisms contribute to resistance development, including mutations in drug target genes, overexpression of efflux pumps, alterations in membrane sterol composition, biofilm formation, and adaptive stress responses. The widespread use of antifungal agents in both clinical medicine and agriculture has been implicated in the selection and dissemination of resistant strains. For example, environmental exposure to agricultural azole fungicides has been associated with the emergence of azole-resistant *Aspergillus fumigatus*, posing a significant threat to public health. Consequently, antifungal susceptibility testing has become an increasingly important component of clinical microbiology laboratories, enabling clinicians to optimize therapeutic strategies and monitor resistance trends. Despite substantial advances, several challenges remain in the diagnosis and control of fungal diseases. Resource-limited settings often lack access to advanced molecular diagnostics and susceptibility testing facilities, resulting in delayed diagnosis and inappropriate treatment. Furthermore, the clinical manifestations of fungal infections are frequently nonspecific and can mimic bacterial, viral, or noninfectious conditions, complicating diagnosis. The integration of molecular diagnostics, genomic surveillance, artificial intelligence–assisted data analysis, and point-of-care testing holds promise for improving the detection and management of fungal infections in the future. Continued research into fungal biology, host–pathogen interactions, and novel antifungal agents will be essential to address the growing burden of fungal diseases and the escalating problem of antifungal resistance. Overall, the evolving field of clinical microbiology remains central to advancing the diagnosis, treatment, and prevention of fungal infections, ultimately contributing to improved patient care and public health outcomes.

## Conclusion

Fungal infections continue to represent a significant and growing challenge in modern healthcare, contributing substantially to morbidity and mortality worldwide, particularly among immunocompromised and critically ill patients. The field of clinical microbiology plays a pivotal role in the detection, identification, and management of these infections, providing essential information that guides timely therapeutic interventions and improves patient outcomes. Over the past decade, remarkable advances have been made in fungal diagnostics, ranging from conventional microscopy and culture-based methods to sophisticated molecular and proteomic technologies. Techniques such as polymerase chain reaction (PCR), next-generation sequencing, antigen detection assays, and MALDI-TOF mass spectrometry have enhanced the speed, accuracy, and sensitivity of fungal pathogen identification, enabling earlier diagnosis and more targeted treatment strategies. Despite these advances, the increasing emergence of antifungal resistance remains a major global concern. Resistance mechanisms involving genetic mutations, efflux pump overexpression, biofilm formation, and alterations in drug targets have reduced the effectiveness of several frontline antifungal agents. The rise of multidrug-resistant pathogens, particularly *Candida auris* and resistant strains of *Aspergillus fumigatus*, underscores the urgent need for continuous surveillance, routine antifungal susceptibility testing, and responsible antifungal stewardship practices.

Furthermore, disparities in access to advanced diagnostic tools and specialized laboratory services continue to hinder effective fungal disease management in many resource-limited settings. The future of clinical mycology lies in the integration of innovative diagnostic platforms, genomic technologies, and global surveillance networks to facilitate rapid pathogen detection and real-time monitoring of resistance trends. Continued research into fungal pathogenesis, host–pathogen interactions, and the development of novel antifungal compounds is essential to address emerging threats and overcome current therapeutic limitations. In conclusion, a comprehensive understanding of the clinical microbiology of fungal infections—from diagnosis to drug resistance—is fundamental for improving disease management, guiding evidence-based treatment decisions, and reducing the global burden of fungal diseases. Strengthening diagnostic capacity, enhancing surveillance efforts, and promoting interdisciplinary collaboration will be critical in meeting the evolving challenges posed by fungal pathogens in the years ahead.

## Acknowledgments

None

## Conflicts of interest

The author declares that there are no conflicts of interest.

## References

1. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. *Science*. 2012;336(6082):647–647.
2. Köhler JR, Hube B, Puccia R, Casadevall A, Perfect JR. Fungi that infect humans. *Microbiol Spectr*. 2017;5(3):10.
3. von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection. *Dtsch Arztebl Int*. 2019;116(16):271–278.
4. Perfect JR. The antifungal pipeline: a reality check. *Nat Rev Drug Discov*. 2017;16(9):603–616.

**Citation:** Ranganathan V, Madham P. Clinical microbiology of fungal infections: from diagnosis to drug resistance. *J Bacteriol Mycol Open Access*. 2026;14(2):74–80. DOI: 10.15406/jbmoa.2026.14.00433

5. Lee PP, Lau YL. Cellular and molecular defects underlying invasive fungal infections—revelations from endemic mycoses. *Front Immunol*. 2017;8:735.
6. Friedman DZP, Schwartz IS. Emerging fungal infections: new patients, new patterns, and new pathogens. *J Fungi (Basel)*. 2019;5(3):67.
7. Terrero-Salcedo D, Powers-Fletcher MV. Updates in laboratory diagnostics for invasive fungal infections. *J Clin Microbiol*. 2020;58(6):e01487-e01519
8. van de Veerdonk FL, Gresnigt MS, Romani L, et al. *Aspergillus fumigatus* morphology and dynamic host interactions. *Nat Rev Microbiol*. 2017;15(11):661–674.
9. Li Z, Nielsen K. Morphology changes in human fungal pathogens upon interaction with the host. *J Fungi (Basel)*. 2017;3(4):66.
10. Garcia-Rubio R, de Oliveira HC, Rivera J, et al. The fungal cell wall: *Candida*, *Cryptococcus*, and *Aspergillus* species. *Front Microbiol*. 2020;10:2993.
11. Lohse MB, Gulati M, Johnson AD, et al. Development and regulation of single- and multi-species *Candida albicans* biofilms. *Nat Rev Microbiol*. 2018;16(1):19–31.
12. Bairwa G, Jung WH, Kronstad JW. Iron acquisition in fungal pathogens of humans. *Metallomics*. 2017;9(2):215–227.
13. Culibrk L, Croft CA, Tebbutt SJ. Systems biology approaches for host–fungal interactions: an expanding multi-omics frontier. *OMICS*. 2016;20(3):176–186.
14. Garbe E, Vylkova S. Role of amino acid metabolism in the virulence of human pathogenic fungi. *Curr Clin Microbiol Rep*. 2019;6:108–119.
15. Casadevall A, Coelho C, Alanio A. Mechanisms of *Cryptococcus neoformans*-mediated host damage. *Front Immunol*. 2018;9:855.
16. Terrero-Salcedo D, Powers-Fletcher MV. Updates in laboratory diagnostics for invasive fungal infections. *J Clin Microbiol*. 2020;58(6):e01487-19.
17. Rath PM, Steinmann J. Overview of commercially available PCR assays for the detection of *Aspergillus* spp. DNA in patient samples. *Front Microbiol*. 2018;9:740.
18. Kidd SE, Chen SCA. A new age in molecular diagnostics for invasive fungal disease: are we ready? *Front Microbiol*. 2020;10:2903.
19. Falci DR, Stadnik CMB, Pasqualotto AC. A review of diagnostic methods for invasive fungal diseases: challenges and perspectives. *Infect Dis Ther*. 2017;6(2):241–255.
20. Patterson TF, Donnelly JP. New concepts in diagnostics for invasive mycoses: non-culture-based methodologies. *J Fungi (Basel)*. 2019;5(1):9.
21. Warris A, Lehrnbecher T. Progress in the diagnosis of invasive fungal disease in children. *Curr Fungal Infect Rep*. 2017;11:35–44.
22. Arvanitis M, Anagnostou T, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. *Clin Microbiol Rev*. 2014;27(3):490–526.
23. Ruhnke M, Rickerts V, Cornely OA, et al. Diagnosis of invasive fungal infections in hematology and oncology: 2017 update of the recommendations of the infectious diseases working party. *Ann Oncol*. 2017;28(3):527–544.
24. Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. *Front Med (Lausanne)*. 2016;3:11.
25. Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in *Candida albicans* and emerging non-albicans *Candida* species. *Front Microbiol*. 2016;7:2173.
26. Hagiwara D, Watanabe A, Kamei K, et al. Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi. *Front Microbiol*. 2016;7:1382.
27. Gonçalves SS, Souza ACR, Chowdhary A, et al. Epidemiology and molecular mechanisms of antifungal resistance in *Candida* and *Aspergillus*. *Mycoses*. 2016;59(4):198–219.
28. Berman J, Krysan DJ. Drug resistance and tolerance in fungi. *Nat Rev Microbiol*. 2020;18(6):319–331.
29. Lee Y, Robbins N, Cowen LE. Molecular mechanisms governing antifungal drug resistance. *NPJ Antimicrob Resist*. 2023;1:5.
30. Lockhart SR, Chowdhary A, Gold JAW. The rapid emergence of antifungal-resistant human-pathogenic fungi. *Nat Rev Microbiol*. 2023;21:818–832.
31. Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. *Virulence*. 2017;8(6):658–672.
32. Chakrabarti A, Mohamed N, Capparella MR, et al. The role of diagnostics-driven antifungal stewardship in the management of invasive fungal infections: a systematic literature review. *Open Forum Infect Dis*. 2022;9(7):ofac234.
33. Kara E, Şahin N, Yumrucu FG, Metan G. Pharmacist involvement in antifungal stewardship programs: a systematic review of clinical, utilization, and economic outcomes. *Int J Clin Pharm*. 2026.
34. Gupta AK, Mann A, Ravi SP, et al. Navigating fungal infections and antifungal stewardship: drug resistance, susceptibility testing, therapeutic drug monitoring and future directions. *Ital J Dermatol Venereol*. 2024;159(2):105–117.
35. Bassetti M, Giacobbe DR, Vena A, et al. Empirical therapy for invasive candidiasis in critically ill patients. *Curr Fungal Infect Rep*. 2024;18:136–145.
36. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. *Science*. 2012;336(6082):647. (Foundational but still widely cited in modern management literature)
37. Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the Mycoses study group education and research consortium. *J Infect Dis*. 2020;222(Suppl 1):S175–S198.
38. Arvanitis M, Anagnostou T, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. *Clin Microbiol Rev*. 2017;27(3):490–526.
39. Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. *J Fungi (Basel)*. 2017;3(4):57.
40. Latgé JP, Chamilos G. *Aspergillus fumigatus* and *aspergillosis* in 2019. *Clin Microbiol Rev*. 2019;33(1):e00140.


**Citation:** Ranganathan V, Madham P. Clinical microbiology of fungal infections: from diagnosis to drug resistance. *J Bacteriol Mycol Open Access*. 2026;14(2):74–80. DOI: 10.15406/jbmoa.2026.14.00433